Valeant Pharmaceuticals Intl Inc (TSE:VRX) Insider Acquires C$241,500.00 in Stock

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) insider Paul Herendeen acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The shares were acquired at an average price of C$16.10 per share, for a total transaction of C$241,500.00.

Shares of TSE:VRX opened at C$19.73 on Friday. Valeant Pharmaceuticals Intl Inc has a 1-year low of C$11.20 and a 1-year high of C$30.56.

How to Become a New Pot Stock Millionaire

Valeant Pharmaceuticals Intl (TSE:VRX) (NYSE:VRX) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported C$1.24 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$1.24. The company had revenue of C$2.75 billion during the quarter, compared to the consensus estimate of C$2.73 billion. Valeant Pharmaceuticals Intl had a net margin of 58.58% and a return on equity of 112.73%.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals Intl Inc (TSE:VRX) Insider Acquires C$241,500.00 in Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with's FREE daily email newsletter.

Leave a Reply